Abstract
We would like to share ideas on the publication, “Association of the Interleukin 1B-31*C Proinflammatory Allele with the Severity of COVID-19 Patients: A Preliminary Report.” (Galán-Huerta et al., 2023). In hospitalized patients in Mexico without known comorbidities, Galán-Huerta et al. (2023) evaluated the impact of certain host polymorphisms and viral lineage on the severity of COVID-19. There was no correlation between SARS-CoV-2 clades and intensive care unit (ICU) hospitalization or death, Galán-Huerta et al. (2023) came to the conclusion that the IL1B-31*C proinflammatory allele was shown to be related to the risk of ICU admission due to COVID-19 in individuals without known comorbidities or risk factors.
The impact of a polymorphism is investigated in this study. This article's explanation of hereditary factors may or may not have an impact. We both agree that the genetic component under investigation may be connected to the predicted result. However, the severity of COVID-19 is linked to a number of genetic variants, including TMPRSS2 and HLA polymorphisms (Akcay et al., 2023; Yaghoobi et al., 2023). Moreover, there is a likelihood that the clinical manifestation at this time is related to a former asymptomatic COVID-19. The consequences of unanticipated potentially puzzling genetic alterations should be the focus of future research.